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Consideration in designing next generation trials 
D.B. Saris, Netherlands 
Good trials and evidence based treatment selection in the cartilage 
¾FMEBSFFTTFOUJBMBOEUIFMBDLPGTVG¾DJFOUQSPHSFTTJOUIJTBTQFDUPG
our interest in the past 20 years has contributed to the current lack 
of experience, funding, reimbursement and clarity for our patients. 
The concept of evidence-based clinical practice involves integrating 
QFSTPOBM FYQFSJFODFXJUI UIF CFTU BWBJMBCMF TDJFOUJ¾D JOGPSNBUJPO
when making decisions about the care of patients. We should accept 
the responsibility for improving the knowledge and thus discuss the 
proper methods and possible limitations to cartilage trial design. 
When reading an article of interest in the orthopedic literature it is 
necessary to appraise the quality of the evidence therein. First, the 
reader should determine the design of the study. If the level of the 
study design in the hierarchy of evidence is lower, the inferences 
that are drawn from the study are weaker. Second, the article should 
be assessed for the quality indicators relevant to the design. To the 
extent that the quality is high, the inferences that are drawn from 
the study will be strengthened. Making this process explicit, with 
guidelines to assess the strength of the available evidence, will 
serve to improve patient care. There are very few published studies 
that have compared the different cartilage repair techniques and 
they are hindered by methodological limitations while the results 
BSF SBUIFS DPO¿JDUJOH +BLPCTFO BEESFTTFE UIF NFUIPEPMPHJDBM
MJNJUBUJPOT PG DBSUJMBHF SFQBJS USJBMT CZ DBMDVMBUJOH UIF NPEJ¾FE
Coleman Methodology Score, a scoring system that considers 
(1) study size (2) mean follow-up (3) number of different surgical 
procedures included in each reported outcome (4) type of the 
study (randomized controlled, prospective or retrospective cohort) 
(5) diagnostic certainty (6) description of surgical procedure (7) 
description of postoperative rehabilitation. Other aspects such as (8) 
outcome criteria, (9) the procedure for assessing outcome and (10) 
the description of subject selection are also taken into consideration. 
)F DPODMVEFE UIBU ¾SN SFDPNNFOEBUJPOT PO XIJDI QSPDFEVSF UP
choose cannot be given on the basis of the limited existing evidence. 
From the 61 studies included in the analysis, only 4 were randomized 
controlled trials. Major effort is made by orthopedic journals to more 
clearly indicate the level of evidence of publications, but there is still 
room for improvement as the level-of-evidence-rating does not take 
into account all areas of sound study design. Some guidelines were 
proposed for future studies, including : (1). a prospective design with 
BDMFBSMZEF¾OFEIZQPUIFTJTBDMFBSMZEF¾OFEQSJNBSZFOEQPJOUBO
adequate randomization procedure and a power analysis for the 
primary endpoint (2). established (and reported) in-and exclusion 
criteria (3). the use of validated outcome measures (4). independent 
investigators for outcome assessment at a clearly stated time point 
(5). detailed and standardized rehabilitation protocols, applied to 
both patient groups. 
5IFTF HVJEFMJOFT SFRVJSF TPNF DMBSJ¾DBUJPO BT EJTUSBDUJOH TJEF
paths can be taken even within the framework of these directives. 
An adequate randomization procedure is a potential pitfall in a 
randomized-controlled trial (RCT) and truly random methods include 
a computer-generated sequence, a coin toss or hand-picking sealed 
envelopes. In such cases, the investigator does not know to which 
group the patient will be designated until the patient has consented 
to the study and is ready for treatment. However even then small 
block randomization and envelopes introduce the possibility of 
¿BXT4UVEJFTXJUIMPXOVNCFSTBSFBUSJTLGPSDPNNJUUJOHXIBUJT
known as beta error, which means that a study concludes that there 
JTOPTUBUJTUJDBMMZTJHOJ¾DBOUEJGGFSFODFXIFOBEJGGFSFODFNJHIUFYJTU
*UJTFTTFOUJBMUPVOEFSTUBOEUIBUOPU¾OEJOHBEJGGFSFODFJTEPFTOPU
mean that two treatments will produce the same outcome. Type 
II (or beta) error is quite frequent in orthopedic trials. Lochner et 
al . found that over 90% of the 117 RCTs reviewed had beta error 
for their primary outcome. This demonstrates the importance of a 
power analysis in order to estimate the sample size needed to prove 
or disprove a difference between two treatment groups. The smaller 
the anticipated difference between treatment groups, the larger the 
number of patients needed to power the study. Unlike drug trials in 
which both the investigator and the patient can easily be blinded to 
UIFUSFBUNFOUUZQFTVSHJDBMUSJBMTCZUIFJSOBUVSFBSFNPSFEJG¾DVMU
to perform in a blind fashion and placebo control is not realistic. 
Alternatively blinded post-operative assessors or independent 
investigators can be involved. This solution is also not possible in 
all cases e.g. when comparing procedures with different surgical 
approach or technique. When planning a comparison of two surgical 
techniques, it is of major importance to ensure that the participating 
surgeons are equivalently adept and familiar with both techniques. 
If a clinical outcome score is used as a primary outcome, the validity, 
repeatability and usability of the outcome instrument must be 
considered. Measurement (or alpha) error is not unique to clinical 
outcome scores, histological and radiographic outcomes must also 
CFDBSFGVMMZTDSVUJOJ[FEBOEEF¾OFECZBTQFDJ¾DTFUPGDSJUFSJB *O
statistically analyzing the results of any orthopedic trial, one must 
BMTPDPOTJEFSXIBUBTUBUJTUJDBMMZTJHOJ¾DBOUEJGGFSFODFNFBOT8IJMF
it is often immediately interpreted as a truthful difference, it really 
SF¿FDUTUIFQSPCBCJMJUZUIBUUIFEJGGFSFODFEJEOPUPDDVSCZDIBODF
What is the clinical relevance of the difference suggested and does 
this change the treatment strategy? In large trials a very large volume 
of data will become available and one should understand that when 
performing extensive data evaluations chance occurrence plays a 
TUBUJTUJDBMMZJNQPSUBOUSPMFJOBTNBOZBTPG¾OEJOHT8IJMFB
p-value less than 0.05 is the most common cut-off point for declaring 
B TUBUJTUJDBMMZ TJHOJ¾DBOUEJGGFSFODFNPSF TUSJOHFOU DSJUFSJB DBOCF
used. This is e.g. the case when using the Bonferroni correction . 
The Bonferroni correction is a method of adjustment that can be 
used when performing multiple analyses. This statistical method 
EFDSFBTFT UIF MJLFMJIPPE UIBU B UUFTU XJMM SFTVMU JO B TJHOJ¾DBOU
difference by lowering the p-value (typically 0.05) and the calculation 
is performed by dividing by the number of outcomes tested. 
With the ever-increasing body of data on cartilage repair and 
SFHFOFSBUJPO JUCFDPNFTNPSFBOENPSFEJG¾DVMU UPEFDJEFPO UIF
appropriate method of randomization and selecting the proper 
comparison treatment. Comparing to natural sequence of events 
is not acceptable but what is the current treatment of choice ? If 
we are to compare biological repair in 3rd generation cartilage 
biotechnology trials should we still compare to microfracturing or 
BSFXFUIFODSFBUJOHBOBSUJ¾DJBMBEWBOUBHFGPSUIFOPWFMUIFSBQZ 
However if we would want to compare matrixbased techniques or 
intelligent biomaterials with current ACI the expected differences 
may be so small that required numbers may become so large that 
the successful execution of the trial would be unlikely and very 
costly. In addition we are now faced with an interesting dilemma 
since long-term follow up of trials is essential in orthopaedics and 
we should understand that communication of short-term results will 
IBWFBOJO¿VFODFPOMPOHUFSNPVUDPNF5IJTDSFBUFTBOJOUFSFTUJOH
discussion since communication of the early results is essential 
for other clinicians, patients, future trial design and towards the 
patients who gave us their trust by consenting to enrolment in trial 
related surgical procedures. Last but not least, patient recruitment 
and retention currently represents a critical bottleneck in all areas 
of clinical research. More than 80% of global trials fail to enroll on 
time, with 52% delayed by 1-6 months. Once enrollment is complete, 
the challenge is keeping patients interested, participating, and 
committed throughout the course of the clinical trial. Many 
recruitment problems stem largely from a lack of awareness about 
clinical research and the critical need for clinical trials in order to 
develop innovative new treatments. 
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